Celltrion signs Incubation agreement with Emory University

Agreement will cover research on new mechanisms to prevent ischemic heart disease and stroke, and development of atherosclerosis drug candidates; Celltrion will have preferential right to license-in new drug candidates

Register for free to listen to this article
Listen with Speechify
INCHEON, Korea—Celltrion, Inc. announced today that they have signed an Incubation agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. An Incubation agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space, facilities, manpower and business operation consulting, to an external research institute or startup in order to support and ensure the autonomy of the research aimed at developing new drugs or next-generation technology, on the condition that the company can preferentially discuss commercialization of the research output.
Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide the research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.
“We are delighted to cooperate with the internationally renowned research team at Emory University led by Dr. Hanjoong Jo, John and Jan Portman Endowed Professor and Associate Chair in the Department of Biomedical Engineering and the Division of Cardiology, who is a leader in the area of mechanically regulated genes in atherosclerosis research,” says the official of Celltrion. “Based on this Incubation agreement, Celltrion will make further plans to secure more various new drugs and technologies. We are hoping that more research institutes and corporations will take an interest in our open innovation.”
Atherosclerosis is a vascular disease in which the blood vessels are narrowed or clogged, due to plaque made up of fat, cholesterol, immune cells and vascular wall cells in the blood vessel. This results in ischemic heart diseases (e.g., myocardial infarction and angina), stroke and peripheral arterial disease. Ischemic heart disease and stroke are the world’s leading causes of death, accounting for a combined 15.2 million deaths worldwide in 2016.
Statins that lower cholesterol and lipid levels in blood are widely used to alleviate the onset and progression of atherosclerosis. Despite the success of lipid lowering drugs, atherosclerotic diseases continue to be the major cause of death worldwide. This highlights the need to develop new drugs that can complement the lipid lowering drugs by targeting new mechanisms of action to prevent and reduce the risk of atherosclerotic diseases.
Celltrion has also recently announced a plan of launching Bio CDMO (Contract Development and Manufacturing Organization) business, in a bid to pursue open innovation for development of new drugs. Celltrion specializes in research, development and manufacture of biosimilars, saying they strive to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue